The current management of diabetic dyslipidaemia

Acta Diabetologica

Volumn 38, Issue 5, 2001, Pages

  Betteridge, D J ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Atorvastatin; Diabetic dyslipidaemia; HMG CoA reductase inhibitors; Lipid lowering

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

ADULT; AGED; ATHEROGENESIS; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS;

EID: 0035673882     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920170004     Document Type: Conference Paper

References (34)

1. Epidemiology of macrovascular disease in diabetes
2. Impact of diabetes on mortality after the first myocardial infarction
3. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged ≥65 years (report from the Coronary Artery Surgery Study [CASS] Registry)
4. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
5. Glucose intolerance, physical signs of peripheral artery disease, and risk of cardiovascular events: The Framingham Study
6. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study
7. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
8. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin dependent) diabetic and non-diabetic subjects
9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)
10. Diabetic dyslipidaemia
11. LDL heterogeneity: Implications for atherogenicity in insulin resistance and NIDDM
12. Type III hyperlipoproteinaemia (dysbetalipoproteinaemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism
13. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results from the Framingham Offspring Study
14. Fasting hypertriglyceridaemia in non-insulin dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities
15. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
16. Asymptomatic hyperglycaemia and cardiovascular risk factors in the elderly
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
18. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
19. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
20. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
21. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
22. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study
23. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
24. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint of European and other Societies on coronary prevention
25. Management of dyslipidemia in adults with diabetes
26. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
27. Comparison of statins in hypertriglyceridaemia
28. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
29. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
30. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
31. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
32. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
33. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia